INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1

CUSIP: 45845PAB4

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class
Debt / NOTE 2.000% 5/1
Market price (% of par)
80.42%
Total 13F principal
$56,641,230
Principal change
+$5,000,000
Total reported market value
$64,964,565
Number of holders
9
Value change
+$4,016,734
Number of buys
3

Quarterly Holders Quick Answers

What is CUSIP 45845PAB4?
CUSIP 45845PAB4 identifies 45845PAB4 - INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 as of Q2 2023

As of 30 Jun 2023, INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 was held by 9 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $56,641,230 in principal (par value) of the bond. The largest 9 bondholders included FRANKLIN RESOURCES INC, OAKTREE CAPITAL MANAGEMENT LP, PenderFund Capital Management Ltd., Calamos Advisors LLC, UBS ASSET MANAGEMENT AMERICAS INC, Russell Investments Group, Ltd., DG Capital Management, LLC, GABELLI & Co INVESTMENT ADVISERS, INC., and Context Capital Management, LLC. This page lists 9 institutional bondholders reporting positions for the Q2 2023 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.